WOS

Permanent URI for this collectionhttps://hdl.handle.net/11443/932

Browse

Author: search.filters.author.Coskun, A.Subject: search.filters.subject.CTX

Search Results

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of beta-isomerized C-terminal telopeptide of type I collagen (beta-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein-a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabolism
    (SPRINGER LONDON LTD, 2020-01-01) Cavalier, E.; Lukas, P.; Bottani, M.; Aarsand, A. K.; Ceriotti, F.; Coskun, A.; Diaz-Garzon, J.; Fernandez-Calle, P.; Guerra, E.; Locatelli, M.; Sandberg, S.; Carobene, A.; Metab, I. O. F.-I.F.C.C. Committee Bone; Che, European Federation Clinical
    We have calculated the biological variation (BV) of different bone metabolism biomarkers on a large, well-described cohort of subjects. BV is important to calculate reference change value (or least significant change) which allows evaluating if the difference observed between two consecutive measurements in a patient is biologically significant or not. Introduction Within-subject (CVI) and between-subject (CVG) biological variation (BV) estimates are essential in determining both analytical performance specifications (APS) and reference change values (RCV). Previously published estimates of BV for bone metabolism biomarkers are generally not compliant with the most up-to-date quality criteria for BV studies. We calculated the BV and RCV for different bone metabolism markers, namely beta-isomerized C-terminal telopeptide of type I collagen (beta-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin (OC), intact fibroblast growth factor 23 (iFGF-23), and uncarboxylated-unphosphorylated Matrix-Gla Protein (uCuP-MGP) using samples from the European Biological Variation Study (EuBIVAS). Methods In the EuBIVAS, 91 subjects were recruited from six European laboratories. Fasting blood samples were obtained weekly for ten consecutive weeks. The samples were run in duplicate on IDS iSYS or DiaSorin Liaison instruments. The results were subjected to outlier and variance homogeneity analysis before CV-ANOVA was used to obtain the BV estimates. Results We found no effect of gender upon the CV(I)estimates. The following CV(I)estimates with 95\% confidence intervals (95\% CI) were obtained: beta-CTX 15.1\% (14.4-16.0\%), PINP 8.8\% (8.4-9.3\%), OC 8.9\% (8.5-9.4\%), iFGF23 13.9\% (13.2-14.7\%), and uCuP-MGP 6.9\% (6.1-7.3\%). Conclusions The EuBIVAS has provided updated BV estimates for bone markers, including iFGF23, which have not been previously published, facilitating the improved follow-up of patients being treated for metabolic bone disease.